Homologous recombination

Homologous recombination

Homologous recombination

On this page

HR Mechanism - The Sister-Act Rescue

⭐ Homologous recombination is a high-fidelity, error-free mechanism for repairing double-strand DNA breaks, primarily active in the S and G2 phases of the cell cycle when a sister chromatid is available as a template.

  • Repairs double-strand breaks (DSBs), primarily active in the S/G2 phase.
  • Uses the undamaged sister chromatid as a perfect template, ensuring a high-fidelity, error-free outcome.

Homologous Recombination vs. Non-Homologous End Joining

Key Proteins - The Repair Crew

  • Damage Sensors & Initiators:
    • ATM (Ataxia-Telangiectasia Mutated): A master kinase that detects double-strand breaks (DSBs) and activates the repair cascade through phosphorylation.
    • MRN Complex (MRE11-RAD50-NBS1): The first responder. Binds directly to broken DNA ends and helps recruit ATM.
  • Mediators & Loaders:
    • BRCA1 & PALB2: Act as scaffolds, recruiting the core machinery. PALB2 links BRCA1 to BRCA2.
    • BRCA2: Essential for loading the RAD51 recombinase onto the processed single-stranded DNA.
  • Core Recombinase:
    • RAD51: The central enzyme that forms a filament on ssDNA, enabling the search for homology and subsequent strand invasion.

Exam Favorite: Mutations in BRCA1 and BRCA2 genes, key mediators of homologous recombination, are strongly associated with hereditary breast and ovarian cancers.

Clinical Correlations - When Good Repair Goes Bad

Synthetic lethality in BRCA-mutated cancers with PARPi

  • Hereditary Breast & Ovarian Cancer (HBOC):
    • Mutations in BRCA1 & BRCA2 genes impair HR, conferring a high lifetime risk for breast, ovarian, prostate, and pancreatic cancers.
  • Fanconi Anemia:
    • Rare genetic disorder with mutations in genes essential for repairing DNA crosslinks, involving the HR pathway.
    • Presents with bone marrow failure, physical anomalies, and ↑ cancer risk (AML, squamous cell carcinoma).
  • Ataxia-Telangiectasia:
    • Mutation in the ATM gene, a kinase that activates HR proteins (e.g., BRCA1).
    • Features cerebellar ataxia, telangiectasias, immunodeficiency, and ↑ cancer predisposition (lymphoma, leukemia).

⭐ The concept of synthetic lethality is exploited by PARP inhibitors (e.g., Olaparib). These drugs are particularly effective against cancers with BRCA1/2 mutations because the cell has lost both its major DNA repair pathways, leading to targeted cell death.

HR vs. NHEJ - A Tale of Two Fixes

Homologous Recombination vs. Non-Homologous End Joining

FeatureHomologous Recombination (HR)Non-Homologous End Joining (NHEJ)
FidelityHigh (Error-free)Low (Error-prone)
Cell CycleS/G2 PhaseG1 Phase
TemplateSister ChromatidNone
SpeedSlowFast
Key ProteinsBRCA1/2, RAD51Ku70/80, DNA-PKcs

High‑Yield Points - ⚡ Biggest Takeaways

  • Homologous Recombination (HR) is a high-fidelity, error-free DNA repair mechanism for double-strand breaks (DSBs).
  • It primarily occurs during the late S and G2 phases of the cell cycle, using an undamaged sister chromatid as a template.
  • Key proteins essential for HR include BRCA1 and BRCA2.
  • Mutations in BRCA1/2 are strongly linked to hereditary breast, ovarian, and prostate cancers.
  • PARP inhibitors are synthetically lethal to HR-deficient cells, a key cancer therapy principle.

Practice Questions: Homologous recombination

Test your understanding with these related questions

A 42-year-old woman is seen by her primary care physician for her annual checkup. She has no current concerns and says that she has been healthy over the last year except for a bout of the flu in December. She has no significant past medical history and is not currently taking any medications. She has smoked 1 pack per day since she was 21 and drinks socially with her friends. Her family history is significant for prostate cancer in her dad when he was 51 years of age and ovarian cancer in her paternal aunt when she was 41 years of age. Physical exam reveals a firm, immobile, painless lump in the upper outer quadrant of her left breast as well as 2 smaller nodules in the lower quadrants of her right breast. Biopsy of these lesions shows small, atypical, glandular, duct-like cells with stellate morphology. Which of the following pathways is most likely abnormal in this patient?

1 of 5

Flashcards: Homologous recombination

1/10

Nonhomologous End Joining (NHEJ) occurs _____ S phase of the cell cycle

TAP TO REVEAL ANSWER

Nonhomologous End Joining (NHEJ) occurs _____ S phase of the cell cycle

before (before/after?)

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial